Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 369

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Targeting p38 MAPK pathway for the treatment of Alzheimer's disease

Munoz, Lenka, Ammit, Alaina J.·2010·Neuropharmacology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2009.11.010

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 89

  1. Ashwell, 2006, The many paths to p38 mitogen-activated protein kinase activation in the immune system, Nat. Rev. Immunol., 6, 532, 10.1038/nri1865 · DOI · Paper page
  2. Avital, 2003, Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity, Hippocampus, 13, 826, 10.1002/hipo.10135 · DOI · Paper page
  3. Bains, 2007, Glia: they make your memories stick!, Trends Neurosci., 30, 417, 10.1016/j.tins.2007.06.007 · DOI
  4. Barbieri, 2008, Differential crosstalk between P2X7 and arachidonic acid in activation of mitogen-activated protein kinases, Neurochem. Int., 53, 255, 10.1016/j.neuint.2008.05.001 · DOI
  5. Barone, 2001, SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia, J. Pharmacol. Exp. Ther., 296, 312, 10.1016/S0022-3565(24)38747-6 · DOI · Paper page
  6. Bernardo, 2006, PPAR-gamma agonists as regulators of microglial activation and brain inflammation, Curr. Pharm. Des., 12, 93, 10.2174/138161206780574579 · DOI · Paper page
  7. Bhat, 1998, Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures, J. Neurosci., 18, 1633, 10.1523/JNEUROSCI.18-05-01633.1998 · DOI · Paper page
  8. Bhat, 2002, p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells, J. Biol. Chem., 277, 29584, 10.1074/jbc.M204994200 · DOI · Paper page
  9. Bodles, 2005, Secreted β-amyloid precursor protein activates microglia via JNK and p38-MAPK, Neurobiol. Aging, 26, 9, 10.1016/j.neurobiolaging.2004.02.022 · DOI
  10. Bogoyevitch, 2007, A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding, Drug Discov. Today, 12, 622, 10.1016/j.drudis.2007.06.008 · DOI · Paper page
  11. Bohac, 2002, A 24-week randomized, double-blind, placebo-controlled study of the efficacy and tolerability of TNFR: Fc (etanercept) in the treatment of dementia of the Alzheimer type, Neurobiol. Aging, 23
  12. Bolshakov, 2000, Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3–CA1 synapses, Nat. Neurosci., 3, 1107, 10.1038/80624 · DOI · Paper page
  13. Borders, 2008, The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target, BMC Neurosci., 9, S12, 10.1186/1471-2202-9-S2-S12 · DOI
  14. Chen, 2008, Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors, Curr. Pharm. Des., 14, 1490, 10.2174/138161208784480126 · DOI
  15. Chen, 2009, Identification of small-molecule inhibitors of the JIP-JNK interaction, Biochem. J., 420, 283, 10.1042/BJ20081899 · DOI
  16. Churcher, 2006, Tau therapeutic strategies for the treatment of Alzheimer's disease, Curr. Top. Med. Chem., 6, 579, 10.2174/156802606776743057 · DOI
  17. Combs, 1999, Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins, J. Neurosci., 19, 928, 10.1523/JNEUROSCI.19-03-00928.1999 · DOI · Paper page
  18. Culbert, 2006, MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity, J. Biol. Chem., 281, 23658, 10.1074/jbc.M513646200 · DOI · Paper page
  19. Da Silva, 1997, Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes, J. Biol. Chem., 272, 28373, 10.1074/jbc.272.45.28373 · DOI · Paper page
  20. Dambach, 2005, Potential adverse effects associated with inhibition of p38α/β MAP kinases, Curr. Top. Med. Chem., 5, 929, 10.2174/1568026054985911 · DOI
  21. Delgado, 2008, Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels, Glia, 56, 1091, 10.1002/glia.20681 · DOI
  22. Dominguez, 2005, p38 MAP kinase inhibitors: many are made, but few are chosen, Curr. Opin. Drug Discov. Devel., 8, 421
  23. Emsley, 2005, A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients, J. Neurol. Neurosurg. Psychiatry, 76, 1366, 10.1136/jnnp.2004.054882 · DOI · Paper page
  24. Giovannini, 2002, β-Amyloid induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway, Neurobiol. Dis., 11, 257, 10.1006/nbdi.2002.0538 · DOI · Paper page
  25. Goshen, 2007, A dual role for interleukin-1 in hippocampal-dependent memory processes, Psychoneuroendocrinology, 32, 1106, 10.1016/j.psyneuen.2007.09.004 · DOI · Paper page
  26. Götz, 2006, Do axonal defects in tau and APP transgenic animals model axonopathy in Alzheimer's disease?, J. Neurochem., 98, 993, 10.1111/j.1471-4159.2006.03955.x · DOI
  27. Götz, 2007, A decade of tau transgenic animal models and beyond, Brain Pathol., 17, 91, 10.1111/j.1750-3639.2007.00051.x · DOI · Paper page
  28. Griffin, 2006, Interleukin-1 mediates Alzheimer and Lewy body pathologies, J. Neuroinflammation, 3, 5, 10.1186/1742-2094-3-5 · DOI · Paper page
  29. Harper, 2003, MAPKs: new targets for neurodegeneration, Expert Opin. Ther. Targets, 7, 187, 10.1517/14728222.7.2.187 · DOI
  30. Hsieh, 2006, AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss, Neuron, 52, 831, 10.1016/j.neuron.2006.10.035 · DOI · Paper page
  31. Hu, 2007, Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits, Bioorg. Med. Chem. Lett., 17, 414, 10.1016/j.bmcl.2006.10.028 · DOI
  32. Hua, 2002, Role of mitogen-activated protein kinases in inducible nitric oxide synthase and TNFα expression in human fetal astrocytes, J. Neuroimmunol., 126, 180, 10.1016/S0165-5728(02)00055-3 · DOI
  33. Izumi, 2008, Long-term potentiation inhibition by low-level N-methyl-d-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase, Hippocampus, 18, 258, 10.1002/hipo.20383 · DOI
  34. Jana, 2008, Fibrillar amyloid-β peptides activate microglia via TLR2: implications for Alzheimer's disease, J. Immunol., 181, 7254, 10.4049/jimmunol.181.10.7254 · DOI · Paper page
  35. Jeohn, 2002, p38 MAP kinase is involved in lipopolysaccharide-induced dopaminergic neuronal cell death in rat mesencephalic neuron-glia cultures, Ann. N.Y. Acad. Sci., 962, 332, 10.1111/j.1749-6632.2002.tb04078.x · DOI
  36. Jin, 2008, Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease, J. Neuroinflammation, 5, 23, 10.1186/1742-2094-5-23 · DOI · Paper page
  37. Kelleher, 2007, Kinase activities increase during the development of tauopathy in htau mice, J. Neurochem., 103, 2256, 10.1111/j.1471-4159.2007.04930.x · DOI · Paper page
  38. Kim, 2004, Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production, Neurobiol. Aging, 25, 431, 10.1016/S0197-4580(03)00126-X · DOI · Paper page
  39. Lee, 1994, A protein kinase involved in the regulation of inflammatory cytokine biosynthesis, Nature, 372, 739, 10.1038/372739a0 · DOI · Paper page
  40. Lee, 2000, p38 MAP kinase regulates TNF-α production in human astrocytes and microglia by multiple mechanisms, Cytokine, 12, 874, 10.1006/cyto.2000.0688 · DOI
  41. Legos, 2001, SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia, Brain Res., 892, 70, 10.1016/S0006-8993(00)03228-5 · DOI
  42. Legos, 2002, The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury, Eur. J. Pharmacol., 447, 37, 10.1016/S0014-2999(02)01890-3 · DOI
  43. Li, 2003, Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway, J. Neurosci., 23, 1605, 10.1523/JNEUROSCI.23-05-01605.2003 · DOI · Paper page
  44. Liu, 2006, Rational design of inhibitors that bind to inactive kinase conformations, Nat. Chem. Biol., 2, 358, 10.1038/nchembio799 · DOI · Paper page
  45. Matos, 2008, Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades, Neurosci, 156, 898, 10.1016/j.neuroscience.2008.08.022 · DOI · Paper page
  46. McDonald, 1998, β-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes, J. Neurosci., 18, 4451, 10.1523/JNEUROSCI.18-12-04451.1998 · DOI · Paper page
  47. McDonald, 1997, Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia, J. Neurosci., 17, 2284, 10.1523/JNEUROSCI.17-07-02284.1997 · DOI · Paper page
  48. Moult, 2008, Co-activation of p38 mitogen-activated protein kinase and protein tyrosine phosphatase underlies metabotropic glutamate receptor-dependent long-term depression, J. Physiol., 586, 2499, 10.1113/jphysiol.2008.153122 · DOI
  49. Moynagh, 2005, The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain, J. Anat., 207, 265, 10.1111/j.1469-7580.2005.00445.x · DOI
  50. Nam, 2008, 5-Chloroacetyl-2-amino-1,3-selenazoles attenuate microglial inflammatory responses through NF-κB inhibition, Eur. J. Pharmacol., 589, 53, 10.1016/j.ejphar.2008.03.034 · DOI
  51. Nimmrich, 2009, Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric β-amyloid, Rev. Neurosci., 20, 1, 10.1515/REVNEURO.2009.20.1.1 · DOI
  52. Orellana, 2007, Neuroprotective effect of TNFα against the β-amyloid neurotoxicity mediated by CDK5 kinase, Biochim. Biophys. Acta – Mol. Cell Res., 1773, 254, 10.1016/j.bbamcr.2006.10.010 · DOI
  53. Origlia, 2008, Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction, J. Neurosci., 28, 3521, 10.1523/JNEUROSCI.0204-08.2008 · DOI · Paper page
  54. Pargellis, 2002, Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site, Nat. Struct. Mol. Biol., 9, 268, 10.1038/nsb770 · DOI · Paper page
  55. Park, 2007, Anti-inflammatory mechanisms of isoflavone metabolites in lipopolysaccharide-stimulated microglial cells, J. Pharmacol. Exp. Ther., 320, 1237, 10.1124/jpet.106.114322 · DOI
  56. Parvathy, 2009, Aβ peptide conformation determines uptake and interleukin-1α expression by primary microglial cells, Neurobiol. Aging, 30, 1792, 10.1016/j.neurobiolaging.2008.01.011 · DOI
  57. Peifer, 2006, New approaches to the treatment of inflammatory disorders with small molecule inhibitors of p38 MAP kinase, Curr. Top. Med. Chem., 6, 113, 10.2174/156802606775270323 · DOI
  58. Previti, 2006, Dexamethasone diminishes the pro-inflammatory and cytotoxic effects of amyloid beta-protein in cerebrovascular smooth muscle cells, J. Neuroinflammation, 3, 18, 10.1186/1742-2094-3-18 · DOI
  59. Quinn, 2003, Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease, J. Neuroimmunol., 137, 32, 10.1016/S0165-5728(03)00037-7 · DOI · Paper page
  60. Ralay Ranaivo, 2006, Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration, J. Neurosci., 26, 662, 10.1523/JNEUROSCI.4652-05.2006 · DOI
  61. Rothwell, 2003, Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential, Brain Behav. Immun., 17, 152, 10.1016/S0889-1591(02)00098-3 · DOI · Paper page
  62. Ryu, 2004, Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus, Glia, 48, 85, 10.1002/glia.20051 · DOI
  63. Saha, 2007, MAPK p38 regulates transcriptional activity of NF-κB in primary human astrocytes via acetylation of p65, J. Immunol., 179, 7101, 10.4049/jimmunol.179.10.7101 · DOI · Paper page
  64. Scheff, 2003, Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies, Neurobiol. Aging, 24, 1029, 10.1016/j.neurobiolaging.2003.08.002 · DOI · Paper page
  65. Schett, 2008, The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis, Ann. Rheum. Dis., 67, 909, 10.1136/ard.2007.074278 · DOI · Paper page
  66. Schieven, 2005, The biology of p38 kinase: a central role in inflammation, Curr. Top. Med. Chem., 5, 921, 10.2174/1568026054985902 · DOI · Paper page
  67. Sheng, 2001, Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation, Neurochem. Int., 39, 341, 10.1016/S0197-0186(01)00041-9 · DOI · Paper page
  68. Shigematsu, 1992, Reactive microglia/macrophages phagocytose amyloid precursor protein produced by neurons following neural damage, J. Neurosci. Res., 31, 443, 10.1002/jnr.490310306 · DOI
  69. Simard, 2006, Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease, Neuron, 49, 489, 10.1016/j.neuron.2006.01.022 · DOI · Paper page
  70. Simi, 2002, The neuroprotective agents chlomethiazole and SB203580 inhibit IL-1β signalling but not its biosynthesis in rat cortical glial cells, J. Neurochem., 83, 727, 10.1046/j.1471-4159.2002.01178.x · DOI
  71. Sokolova, 2009, Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease, Brain Pathol., 19, 392, 10.1111/j.1750-3639.2008.00188.x · DOI · Paper page
  72. Sparacio, 1992, Cytokine upregulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kappa B-like nuclear protein, J. Neuroimmunol., 39, 231, 10.1016/0165-5728(92)90257-L · DOI
  73. Srinivasan, 2004, Cell type-specific interleukin-1β signaling in the CNS, J. Neurosci., 24, 6482, 10.1523/JNEUROSCI.5712-03.2004 · DOI · Paper page
  74. Tanji, 2003, Interleukin-1 induces tau phosphorylation and morphological changes in cultured human astrocytes, Neuroreport, 14, 413, 10.1097/00001756-200303030-00023 · DOI
  75. Thalhamer, 2008, MAPKs and their relevance to arthritis and inflammation, Rheumatology, 47, 409, 10.1093/rheumatology/kem297 · DOI · Paper page
  76. Tobinick, 2006, TNF-aα modulation for treatment of Alzheimer's disease: a 6-month pilot study, MedGenMed, 8, 25
  77. Tobinick, 2008, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease, BMC Neurol., 8, 27, 10.1186/1471-2377-8-27 · DOI
  78. Tobinick, 2009, Perispinal etanercept for neuroinflammatory disorders, Drug Discov. Today, 14, 168, 10.1016/j.drudis.2008.10.005 · DOI
  79. Van Eldik, 2007, Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches, Int. Rev. Neurobiol., 82, 277, 10.1016/S0074-7742(07)82015-0 · DOI
  80. Volterra, 2005, Astrocytes, from brain glue to communication elements: the revolution continues, Nat. Rev. Neurosci., 6, 626, 10.1038/nrn1722 · DOI · Paper page
  81. White, 2005, Differential effects of oligomeric and fibrillar amyloid-β 1-42 on astrocyte-mediated inflammation, Neurobiol. Dis., 18, 459, 10.1016/j.nbd.2004.12.013 · DOI · Paper page
  82. Wyss-Coray, 2006, Inflammation in Alzheimer disease: driving force, bystander or beneficial response?, Nat. Med., 12, 1005
  83. Xiao-Dong, 2009, Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-κB and JNK signaling, Glia, 57, 1227, 10.1002/glia.20844 · DOI
  84. Xie, 2004, Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38, Glia, 45, 170, 10.1002/glia.10314 · DOI · Paper page
  85. Xing, 2008, Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt, J. Neuroinflammation, 5, 4, 10.1186/1742-2094-5-4 · DOI
  86. Yoshida, 2006, Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope, J. Neurochem., 99, 154, 10.1111/j.1471-4159.2006.04052.x · DOI
  87. Zhao, 2004, 15-Deoxy-[Delta] (12,14)-PGJ2 inhibits astrocyte IL-1 signaling: inhibition of NF-κB and MAP kinase pathways and suppression of cytokine and chemokine expression, J. Neuroimmunol., 153, 132, 10.1016/j.jneuroim.2004.05.003 · DOI
  88. Zhou, 2007, Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia, J. Neurochem., 102, 667, 10.1111/j.1471-4159.2007.04535.x · DOI
  89. Zhu, 2001, Activation of MKK6, an upstream activator of p38, in Alzheimer's disease, J. Neurochem., 79, 311, 10.1046/j.1471-4159.2001.00597.x · DOI · Paper page

Cited by

See all 369

Metadata

Authors
Munoz, L., & Ammit, A. J.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2010-03
Volume
58
Issue
3
Pages
561-568
ISSN
0028-3908 (ISSN-L)
OpenAlex
W1983816589
Cited by
369
References
30
FWCI
8.07
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.neuropharm.2009.11.010
The paper
Munoz, L., & Ammit, A. J. (2010). Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2009.11.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.